BMRA BIOMERICA INC
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 73290 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.2%
TTM net income YoY-37.0%
TTM EPS YoY-9.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin0.9%
Operating margin-125.2%
Net margin-115.5%
FCF margin—
EBITDA margin-123.6%
Returns
ROE-113.8%
ROA-67.1%
ROIC (approx.)-284.4%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets54.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.45M | $5.31M |
| Cost of revenue | $4.09M | $4.81M |
| Gross profit | $362,000 | $498,000 |
| R&D expense | $788,000 | $1.02M |
| SG&A expense | $4.89M | $4.61M |
| Operating income | -$5.32M | -$5.14M |
| Pretax income | -$3.75M | -$4.97M |
| Income tax | $23,000 | $1,000 |
| Net income | -$3.77M | -$4.97M |
| EBITDA | -$5.24M | -$5.05M |
| EPS (basic) | -1.30 | -2.16 |
| EPS (diluted) | -1.30 | -2.16 |
| Weighted avg. shares (diluted) | 2.91M | 2.30M |
| Balance sheet | ||
| Cash & equivalents | $1.31M | $2.40M |
| Receivables | $785,000 | $731,000 |
| Inventory | $1.71M | $1.49M |
| Current assets | $4.02M | $4.88M |
| PP&E, net | $78,000 | $135,000 |
| Intangibles | $209,000 | $228,000 |
| Total assets | $6.76M | $5.95M |
| Current liabilities | $2.48M | $1.74M |
| Total liabilities | $4.13M | $1.84M |
| Shareholders' equity | $2.63M | $4.11M |
| Shares outstanding | 3.20M | 2.55M |
| Cash flow statement | ||
| Operating cash flow | -$3.42M | -$3.84M |
| Investing cash flow | -$1,000 | -$37,000 |
| Financing cash flow | $2.33M | $2.11M |
| Depreciation & amortization | $77,000 | $87,000 |
| Stock-based compensation | $476,000 | $460,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.